Biorestorative Therapies (NASDAQ:BRTX) Shares Up 0.4% – What’s Next?

Biorestorative Therapies, Inc. (NASDAQ:BRTX) shot up 0.4% on Thursday . The company traded as high as $1.18 and last traded at $1.1550. 14,932 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 24,448 shares. The stock had previously closed at $1.15.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Biorestorative Therapies Price Performance

The business’s fifty day moving average price is $1.15 and its 200-day moving average price is $1.41. The stock has a market capitalization of $10.26 million, a PE ratio of -0.79 and a beta of 0.28.

Biorestorative Therapies (NASDAQ:BRTX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.38). Biorestorative Therapies had a negative net margin of 3,308.09% and a negative return on equity of 231.08%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.46 million. On average, analysts expect that Biorestorative Therapies, Inc. will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Biorestorative Therapies

An institutional investor recently raised its position in Biorestorative Therapies stock. Virtu Financial LLC boosted its holdings in Biorestorative Therapies, Inc. (NASDAQ:BRTX) by 102.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,351 shares of the company’s stock after acquiring an additional 12,319 shares during the quarter. Virtu Financial LLC owned 0.31% of Biorestorative Therapies worth $35,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.